- Home
- HBNC vs GALT Comparison
HBNC vs GALT Comparison
Compare HBNC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- GALT
- Stock Information
- Founded
- HBNC 1873
- GALT 2000
- Country
- HBNC United States
- GALT United States
- Employees
- HBNC N/A
- GALT N/A
- Industry
- HBNC Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- GALT Health Care
- Exchange
- HBNC Nasdaq
- GALT Nasdaq
- Market Cap
- HBNC 809.8M
- GALT 147.8M
- IPO Year
- HBNC N/A
- GALT N/A
- Fundamental
- Price
- HBNC $16.48
- GALT $1.04
- Analyst Decision
- HBNC Hold
- GALT Strong Buy
- Analyst Count
- HBNC 2
- GALT 1
- Target Price
- HBNC $18.50
- GALT $11.00
- AVG Volume (30 Days)
- HBNC 178.5K
- GALT 1.1M
- Earning Date
- HBNC 01-22-2025
- GALT 11-13-2024
- Dividend Yield
- HBNC 3.88%
- GALT N/A
- EPS Growth
- HBNC N/A
- GALT N/A
- EPS
- HBNC 0.48
- GALT N/A
- Revenue
- HBNC $183,718,000.00
- GALT N/A
- Revenue This Year
- HBNC N/A
- GALT N/A
- Revenue Next Year
- HBNC $13.76
- GALT N/A
- P/E Ratio
- HBNC $34.13
- GALT N/A
- Revenue Growth
- HBNC N/A
- GALT N/A
- 52 Week Low
- HBNC $11.18
- GALT $0.73
- 52 Week High
- HBNC $19.18
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- HBNC 35.92
- GALT 20.80
- Support Level
- HBNC $17.40
- GALT $1.80
- Resistance Level
- HBNC $17.95
- GALT $2.36
- Average True Range (ATR)
- HBNC 0.54
- GALT 0.27
- MACD
- HBNC -0.26
- GALT -0.08
- Stochastic Oscillator
- HBNC 16.26
- GALT 15.07
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.